Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Benazepril Capsules, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug is approved for production by the National Medical Products Administration, with the registration certificate number 2025S02582 [1]. - Amlodipine Benazepril Capsules are indicated for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those requiring a switch from separate Amlodipine and Benazepril tablets [1]. R&D Investment - The company has invested a total of RMB 8.1616 million (approximately 1.1 million USD) in the research and development of this drug [2]. Market Situation of Similar Drugs - According to data from Minai Network, the sales revenue of Amlodipine Benazepril oral formulations in China is approximately RMB 1.12 billion (about 160 million USD) for 2024 [3]. - The sales distribution includes RMB 727 million (about 102 million USD) from urban public hospitals and county-level public hospitals, RMB 167 million (about 24 million USD) from urban community centers and township health clinics, and RMB 226 million (about 32 million USD) from urban pharmacies and online pharmacies [3]. Impact on the Company - The approval of the drug will enrich the company's product line and enhance its market competitiveness [4].

Macro Highlights - The State Council issued an opinion to release the potential of sports consumption and promote high-quality development of the sports industry, proposing 6 key measures with 20 specific actions [1] - The measures include expanding the supply of sports products, stimulating consumer demand, strengthening sports enterprises, fostering growth points in the sports industry, enhancing support for industry elements, and improving service levels [1] - The National Standardization Administration plans to revise and formulate over 4,000 national standards focusing on key areas such as artificial intelligence and the Internet of Things to support the transformation and upgrading of the manufacturing industry [1] Company News - Jiahe Meikang announced that Hongyun Jiukang plans to reduce its stake in the company by no more than 1% [4] - Bolong Technology's supervisory board chairman intends to reduce his stake by no more than 0.75% [4] - Lianhuan Pharmaceutical received a drug registration certificate for Amlodipine Besylate Tablets [4] - Tianyu Co., Ltd. obtained a drug registration certificate for Candesartan Cilexetil Tablets [4] - Kebo Da plans to acquire 60% of Kebo Da Intelligent Technology for 345 million yuan [4] - Youyan Powder Materials reported that its newly developed heat dissipation copper powder cannot be used as a 3D printing material [4] - Southeast Network Frame won the bid for the joint development project of Wuyuan Street [4] - Lepu Medical completed the first dosing of the Phase II clinical trial for MWN105 injection [4] - Zhonghaidah clarified that its designated robot company is not UBTECH [4] - Information Development aims to expand cooperation opportunities with the Robotaxi industry chain [4] Additional Company News - Jingong Steel Structure's subsidiary won a land bid in Shanghai for 546 million yuan [5] - Fuyuan Pharmaceutical received a drug registration certificate for Amlodipine Benazepril Capsules [5] - Ningbo Construction's subsidiary won construction projects totaling 1.117 billion yuan [5]

Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the production of Amlodipine Benazepril Capsules, marking a significant milestone for the company in expanding its product offerings [1] Group 1 - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule, indicating a combination therapy for hypertension [1] - The drug registration certificate number is 2025S02582, which formalizes the approval process [1]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules, which will enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is classified as a Class 3 chemical drug and is prescribed for patients whose blood pressure is not adequately controlled by Amlodipine or Benazepril alone [1]. - The drug's specifications include 5mg of Amlodipine Besilate and 10mg of Benazepril Hydrochloride per capsule [1]. - The registration certificate number is 2025S02582, and the drug is categorized as a prescription medication [1]. Market Information - The total sales of Amlodipine Besilate and Benazepril Hydrochloride Capsules in China for 2024 are estimated to be approximately 1.12 billion yuan, with sales in urban public hospitals and county-level public hospitals accounting for 727 million yuan [1]. - Sales from urban community centers and township health clinics are projected to be 167 million yuan, while urban pharmacies and online pharmacies are expected to generate 226 million yuan [1]. Company Impact - The approval of the drug registration certificate is expected to enrich the company's product portfolio and improve its market competitiveness [2].

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating a significant milestone for the company in the hypertension treatment market [1]. Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Amlodipine Benazepril Capsules, which contain 5mg of Amlodipine and 10mg of Benazepril per capsule [1]. - This product is intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those who are switching from separate Amlodipine and Benazepril tablets [1]. Group 2: Market Context - Amlodipine Benazepril was originally developed by Novartis and was first approved in the United States in March 1995 [1]. - The original manufacturer’s version of Amlodipine Benazepril has not yet been launched in China, presenting a potential market opportunity for Fuyuan Pharmaceutical [1].

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating approval for production and use in hypertension treatment [1] Group 1: Drug Approval Details - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule and is intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone [1] - The drug was originally developed by Novartis and was first approved in the United States in March 1995 [1] - The company received the application acceptance notice on March 21, 2024, and has now obtained the drug registration certificate, which is considered equivalent to passing the consistency evaluation according to national policies [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating a significant step in expanding its product portfolio in the hypertension treatment market [1]. Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Amlodipine Benazepril Capsules, with the certificate number 2025S02582, allowing the company to commence production [1]. - The capsules contain 5mg of Amlodipine and 10mg of Benazepril, and are intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone [1]. Group 2: Market Context - Amlodipine Benazepril Capsules were originally developed by Novartis and were first approved for sale in the United States in March 1995 [1]. - The original manufacturer’s version of Amlodipine Benazepril Capsules has not yet been launched in China, presenting a potential market opportunity for the company [1].

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiaries have received drug registration certificates for several medications from the National Medical Products Administration [1] Group 1: Company Developments - Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., and Double Crane Pharmaceutical (Hainan) Co., Ltd. have each received drug registration certificates for Amlodipine Benazepril Capsules, Tocilizumab Sustained-Release Tablets, and Valsartan Fumarate Tablets respectively [1]

Policy Developments - The State Council aims to develop the China (Jiangsu) Pilot Free Trade Zone into a globally influential biopharmaceutical industry hub, with a plan that includes 18 key tasks for integrated innovation across the entire industry chain by 2030 [1] Drug Approvals - China Resources Double Crane announced that its subsidiaries received drug registration certificates for three products, which will enhance the company's product line and market competitiveness [2] - Tianyao Pharmaceutical's subsidiary received a drug registration certificate for a new eye drop product, which is expected to positively impact the company's domestic market expansion and performance [3] Financial Reports - China National Pharmaceutical Group reported a revenue of 17.076 billion yuan for the first half of 2025, a decrease of 6.71% year-on-year, with a net profit of 294 million yuan, down 16.19% [4] - Jiahe Meikang reported a revenue of 219 million yuan for the first half of 2025, a decline of 27.22%, resulting in a net loss of 116 million yuan [5] - Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a decrease of 6.20%, but a net profit increase of 3.92% to 1.155 billion yuan [6] Investment Activities - Tibet Pharmaceutical plans to invest 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake, focusing on gene editing technologies [7] Industry Developments - The first long-acting injection for infertility treatment has been approved, providing a more efficient and convenient option for patients compared to traditional daily injections [8] - A study revealed a protein linked to infertility and cancer, suggesting potential new treatment avenues for both conditions [9] Shareholder Actions - Dabo Medical announced a plan for a shareholder to reduce their stake by up to 2% of the company's shares [10] - Kangchen Pharmaceutical's executive plans to sell up to 87,500 shares due to personal financial needs [11]

Core Viewpoint - China Resources Double Crane announced the receipt of drug registration certificates for three products from the National Medical Products Administration, indicating a significant step in expanding its pharmaceutical portfolio [1] Group 1: Company Developments - The wholly-owned subsidiaries of China Resources Double Crane, including Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., and Double Crane Pharmaceutical (Hainan) Co., Ltd., received registration certificates for Amlodipine Benazepril Capsules, Tocilizumab Sustained-Release Tablets, and Vornorex Fumarate Tablets [1]